Randomized Trial of Combined Triple Therapy Comprising Two Types of Peginterferon With Simeprevir in Patients With Hepatitis C Virus Genotype 1b

Hepatology Research - United Kingdom
doi 10.1111/hepr.12689
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Randomized Trial of Peginterferon Alfa-2b and Ribavirin for 48 or 72 Weeks in Patients With Hepatitis C Virus Genotype 1 and Slow Virologic Response

Hepatology
MedicineHepatology
2010English

Prediction of Sustained Virological Response to Telaprevir/Simeprevir-Based Triple Therapy in Patients With Genotype 1 Hepatitis C Virus Using Super-Early Viral Response Within 2 Weeks

Journal of Liver
2017English

An Integrated Analysis of Elbasvir/Grazoprevir in Korean Patients With Hepatitis C Virus Genotype 1b Infection

Clinical and molecular hepatology
MedicineHepatologyMolecular Biology
2019English

Peginterferon Alfa-2b and Ribavirin Therapy in Kuwaiti Patients With Chronic Hepatitis C Virus Infection

Eastern Mediterranean Health Journal
Medicine
2011English

Prediction of Treatment Efficacy and Telaprevir-Resistant Variants After Triple Therapy in Patients Infected With Hepatitis C Virus Genotype 1

Journal of Clinical Microbiology
Microbiology
2013English

Effectiveness of Elbasvir/Grazoprevir in US Veterans With Chronic Hepatitis C Virus Genotype 1b Infection

Infectious Diseases and Therapy
Infectious DiseasesMicrobiology
2020English

A Randomized Trial of 24 Versus 48 Weeks of Peginterferon Α-2a in Patients Infected With Chronic Hepatitis C Virus Genotype 2 or Low Viral Load Genotype 1: A Multicenter National Study in Japan

Hepatology International
Hepatology
2009English

Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in Treatment-Naïve Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis Treated With a Simeprevir/Sofosbuvir/Ledipasvir Regimen

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2017English

A Randomized, Controlled Study of Peginterferon Lambda-1a/Ribavirin ± Daclatasvir for Hepatitis C Virus Genotype 2 or 3

SpringerPlus
Multidisciplinary
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy